

News Release

Mar.30, 2012

Toray Industries, Inc.
Taiho Pharmaceutical Co., Ltd.

Termination of co-development of a β 3-adrenoceptor agonist

Toray Industries, Inc. (Head Office: Chuo-ku, Tokyo; President: Akihiro Nikkaku; hereafter “Toray”) and Taiho Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Toru Usami; hereafter “Taiho”) have been co-developing the β 3-adrenoceptor agonist TRK-380 (Toray development code) / TAC-301 (Taiho development code), which was discovered by Toray, for the treatment of overactive bladder. However, today Toray and Taiho announced that they have agreed to terminate this co-development.

Development is currently at the Phase I clinical trial stage in Japan. Looking towards the continued development of this product, Toray is currently examining future clinical development plans.

<Corporate Data>

Toray Industries, Inc.

Head Office: 2-1-1 Muromachi, Nihonbashi, Chuo-ku, Tokyo

President: Akihiro Nikkaku

Capital: 147, 873 million yen (as for Mar 31, 2011)

Taiho Pharmaceutical Co., Ltd.

Head Office: 1-27 Kandanshiki-cho, Chiyoda-ku, Tokyo

President: Toru Usami

Capital: 200 million yen (as for Mar 31, 2011)

<Contact details for enquiries regarding this press release>

Corporate Communications Department, Toray Industries, Inc. (Tokyo) +81-3-3245-5179

Public Relations Department, Taiho Pharmaceutical Co., Ltd. (Tokyo) +81-3-3293-2878